Neogenomics Inc.

NEO

Nasdaq; other; SIC 8734, Services-Testing Laboratories; CIK 0001077183

C

middle fifth of 315 graded peers in other

rank 175 of 315; percentile 55.4; sampling error 2.7 points; lower is stronger



C, the tortoise



Scoreboard	
Profitability	C/D percentile 61.6
Solvency	B percentile 29.7
Growth and financing	C/D percentile 59.0
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.4B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	9 of 13
Graded from	filings received through Feb 17, 2026 273 days before the rescan; latest periodic filing 10-Q received Oct 28, 2026
Last close	$15.41 2026-11-16; market equity $2.0B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 17, 2026

NeoGenomics, Inc., a Nevada corporation (referred to individually as the "Company" or collectively with its subsidiaries as "NeoGenomics," "we," "us," or "our" in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "NEO." NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 61.6						
Gross profitability	23.1%	26.9%		52.3	265	2025-12-31
Return on invested capital	(10.8%)	10.1%		95.2	146	2025-12-31
Accruals ratio	(7.6%)	(5.8%)		38.7	458	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	2.7 pts	2.1 pts	60.3	195	2025-12-31
Solvency, sleeve percentile 29.7					
Altman Z double-prime	1.46	2.06	50.6	357	2025-12-31
Net debt to EBITDA	not computable	2.37x			
EBITDA must exceed $100,000					
Interest coverage	not computable	2.93x			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	4.26x	1.32x	8.9	462	2025-12-31
Growth and financing, sleeve percentile 59.0					
Revenue growth, three-year compound	12.6%	5.1%	25.8	377	2025-12-31
Free cash flow growth, three-year compound	not computable	8.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	12.4%			
NOPAT must exceed $100,000					
Asset growth, three years	(7.9%)	4.1%	86.0	402	2025-12-31
Net share issuance, one year	1.1%	(0.6%)	65.2	352	2026-02-13

Among 315 peers

other; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
170	Rimini Street, Inc. (RMNI)	53.8	C	fortress balance sheet
171	Choice Hotels International Inc. (CHH)	54.1	C	
172	Union Pacific Corp. (UNP)	54.5	C	
173	Arlo Technologies, Inc. (ARLO)	54.8	C	
174	Vivakor, Inc. (VIVK)	55.1	C	short runway, late filer
175	Neogenomics Inc. (NEO)	55.4	C	
176	United Airlines Holdings, Inc. (UAL)	55.7	C	
177	Life Time Group Holdings, Inc. (LTH)	56.1	C	
178	Hilton Worldwide Holdings Inc. (HLT)	56.4	C	
179	Ameresco, Inc. (AMRC)	56.7	C	
180	Equifax Inc. (EFX)	57.0	C	

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	87.9%	(0.7%)	94
Distance from 52-week high	(22.6%)	(23.6%)	52
EBIT to enterprise value	(5.3%)	4.4%	13
Free cash flow yield	(1.1%)	4.2%	21
Book value to price	0.40	0.36	54
Sales to price	0.36	0.71	33
Composite equity issuance, five years	10.1%	(9.4%)	77

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	0.51	(0.13)	94
Twelve-month failure probability, CHS model	not computable	0.03%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$139.3M
Operating cash flow, four quarters	$4.3M
Months of runway	not finite
Days since last periodic filing	20 (10-Q received Oct 28, 2026)
Median daily dollar volume, 63 sessions	$29.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$314.3M	2025-12-31	2026-02-17	10-K	26-000010
2	assets	us-gaap:Assets	$1.4B	2025-12-31	2026-02-17	10-K	26-000010
3	operating income	us-gaap:OperatingIncomeLoss	-$115.9M	2025-12-31	2026-02-17	10-K	26-000010
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$110.3M	2025-12-31	2026-02-17	10-K	26-000010
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-$2.2M	2025-12-31	2026-02-17	10-K	26-000010
6	total debt	us-gaap:LongTermDebt	$341.9M	2025-12-31	2026-02-17	10-K	26-000010
7	book equity	us-gaap:StockholdersEquity	$836.6M	2025-12-31	2026-02-17	10-K	26-000010
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$159.6M	2025-12-31	2026-02-17	10-K	26-000010
9	total debt	us-gaap:LongTermDebt	$541.1M	2024-12-31	2026-02-17	10-K	26-000010
10	book equity	us-gaap:StockholdersEquity	$902.3M	2024-12-31	2026-02-17	10-K	26-000010
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$367.0M	2024-12-31	2026-02-17	10-K	26-000010
12	net income	us-gaap:NetIncomeLoss	-$108.0M	2025-12-31	2026-02-17	10-K	26-000010
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$5.2M	2025-12-31	2026-02-17	10-K	26-000010
14	assets	us-gaap:Assets	$1.6B	2024-12-31	2026-02-17	10-K	26-000010
15	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$727.3M	2025-12-31	2026-02-17	10-K	26-000010
16	gross profit	us-gaap:GrossProfit	$290.1M	2024-12-31	2026-02-17	10-K	26-000010
17	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$660.6M	2024-12-31	2026-02-17	10-K	26-000010
18	gross profit	us-gaap:GrossProfit	$244.6M	2023-12-31	2026-02-17	10-K	26-000010
19	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$591.6M	2023-12-31	2026-02-17	10-K	26-000010
20	gross profit	us-gaap:GrossProfit	$187.9M	2022-12-31	2025-02-18	10-K	25-000028
21	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$509.7M	2022-12-31	2025-02-18	10-K	25-000028
22	gross profit	us-gaap:GrossProfit	$187.1M	2021-12-31	2024-02-20	10-K	24-000011
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$484.3M	2021-12-31	2024-02-20	10-K	24-000011
24	current assets	us-gaap:AssetsCurrent	$376.3M	2025-12-31	2026-02-17	10-K	26-000010
25	current liabilities	us-gaap:LiabilitiesCurrent	$88.3M	2025-12-31	2026-02-17	10-K	26-000010
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$433.8M	2025-12-31	2026-02-17	10-K	26-000010
27	liabilities	us-gaap:Liabilities	$523.3M	2025-12-31	2026-02-17	10-K	26-000010
28	depreciation amortization	us-gaap:Depreciation	$36.1M	2025-12-31	2026-02-17	10-K	26-000010
29	operating income	us-gaap:OperatingIncomeLoss	-$107.7M	2023-12-31	2026-02-17	10-K	26-000010

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	interest expense	us-gaap:InterestExpense	$6.9M	2023-12-31	2024-02-20	10-K	24-000011
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$27.0M	2025-12-31	2026-02-17	10-K	26-000010
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$7.0M	2024-12-31	2026-02-17	10-K	26-000010
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$41.1M	2024-12-31	2026-02-17	10-K	26-000010
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$2.0M	2023-12-31	2026-02-17	10-K	26-000010
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$28.8M	2023-12-31	2026-02-17	10-K	26-000010
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$66.0M	2022-12-31	2025-02-18	10-K	25-000028
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$30.9M	2022-12-31	2025-02-18	10-K	25-000028
38	current assets	us-gaap:AssetsCurrent	$596.0M	2024-12-31	2026-02-17	10-K	26-000010
39	current liabilities	us-gaap:LiabilitiesCurrent	$301.2M	2024-12-31	2026-02-17	10-K	26-000010
40	assets	us-gaap:Assets	$1.7B	2023-12-31	2025-02-18	10-K	25-000028
41	assets	us-gaap:Assets	$1.7B	2022-12-31	2024-02-20	10-K	24-000011
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	129,812,211	2026-02-13	2026-02-17	10-K	26-000010
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	128,461,383	2025-02-11	2025-02-18	10-K	25-000028

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.